957122-12-2

Basic information

• Product Name: lithium [(3R)-1-(tert-butoxycarbonyl)-3-(3,5-difluorophenyl)-3-methyl-5-oxo-1,4-diazaspiro[5.5]undec-4-yl]acetate
• Synonyms: lithium [(3R)-1-(tert-butoxycarbonyl)-3-(3,5-difluorophenyl)-3-methyl-5-oxo-1,4-diazaspiro[5.5]undec-4-yl]acetate
• CAS NO: 957122-12-2
• Molecular Weight: 458.431
• Mol File: 957122-12-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: lithium [(3R)-1-(tert-butoxycarbonyl)-3-(3,5-difluorophenyl)-3-methyl-5-oxo-1,4-diazaspiro[5.5]undec-4-yl]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: lithium [(3R)-1-(tert-butoxycarbonyl)-3-(3,5-difluorophenyl)-3-methyl-5-oxo-1,4-diazaspiro[5.5]undec-4-yl]acetate(957122-12-2)
• EPA Substance Registry System: lithium [(3R)-1-(tert-butoxycarbonyl)-3-(3,5-difluorophenyl)-3-methyl-5-oxo-1,4-diazaspiro[5.5]undec-4-yl]acetate(957122-12-2)

Safety Data

• Hazardous Substances Data: 957122-12-2(Hazardous Substances Data)

Upstream product

• 321318-29-0 1-(3,5-difluorophenyl)ethylamine 
• 957122-15-5 tert-butyl [1-(3,5-difluorophenyl)-1-methyl-2-oxoethyl]carbamate 
• 957122-13-3 di-tert-butyl [1-(3,5-difluorophenyl)ethyl]imidodicarbonate 
• 957122-14-4 tert-butyl 2-[(tert-butoxycarbonyl)amino]-2-(3,5-difluorophenyl)propanoate 
• 957122-18-8 (3R)-3-(3,5-difluorophenyl)-3-methyl-1,4-diazaspiro[5.5]undecan-5-one 
• 957122-17-7 methyl 1-{[2-amino-2-(3,5-difluorophenyl)propyl]amino}cyclohexane-1-carboxylate 
• 957122-19-9 tert-butyl (3R)-3-(3,5-difluorophenyl)-3-methyl-5-oxo-1,4-diazaspiro[5.5]undecane-1-carboxylate 
• 957122-16-6 methyl 1-{[2-[(tert-butoxycarbonyl)amino]-2-(3,5-difluorophenyl)propyl]amino}cyclohexane-1-carboxylate 
• 123577-99-1 3′,5′-difluoroacetophenone 
• 957122-20-2 tert-butyl (3R)-3-(3,5-difluorophenyl)-4-(2-ethoxy-2-oxoethyl)-3-methyl-5-oxo-1,4-diazaspiro[5.5]undecane-1-carboxylate 

Relevant articles and documents

MONOCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of the formula (I) : (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.